Feed aggregator

Pfizer announces positive top-line data for full season two efficacy of ABRYSVO® for RSV in older adults

World Pharma News - Thu, 02/29/2024 - 11:00
Pfizer Inc. (NYSE: PFE) today announced top-line ABRYSVO® vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the Northern and Southern Hemispheres from the ongoing pivotal Phase 3 clinical trial (NCT05035212) RENOIR (RSV vaccine Efficacy study iNOlder adults Immunized against RSV disease).

Anti-cancer drug could improve symptoms after stroke

World Pharma News - Wed, 02/28/2024 - 11:00
A study by the Institut de Neurociències of the UAB (INc-UAB) demonstrates in animal models the benefits of vorinostat after having suffered a stroke. The drug, used in humans to treat cutaneous T-cell lymphoma, has been proved to mitigate brain injuries and help in restoring brain tissue.

Ischemic stroke is the second leading cause of death worldwide and occurs when blood flow cannot reach the brain due to an obstruction.

Bayer receives U.S. FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations

World Pharma News - Tue, 02/27/2024 - 11:00
Bayer announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy. BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant human epidermal growth factor receptors 2 (HER2),

Innovative chemotherapy approach shows promise against lung cancer

World Pharma News - Mon, 02/26/2024 - 23:55
Lung cancer is not the most common form of cancer, but it is by far the deadliest.

Despite treatments such as surgery, radiation therapy and chemotherapy, only about a quarter of all people with the disease will live more than five years after diagnosis, and lung cancer kills more than 1.8 million people worldwide each year, according to the World Health Organization.

European Commission approves Pfizer's VELSIPITY® for patients with moderately to severely Active ulcerative colitis

World Pharma News - Fri, 02/23/2024 - 11:00
Pfizer Inc. (NYSE: PFE) announced that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.

Researchers find possible solutions to reverse Alzheimer's Disease impact

World Pharma News - Thu, 02/22/2024 - 11:00
University of North Carolina at Chapel Hill researchers have developed a new drug delivery platform that harnesses helical amyloid fibers designed to untwist and release drugs in response to body temperatures.

A new research paper published on Jan. 26 in Nature Communications reveals groundbreaking structural details into how diseases form much like Alzheimer's disease.

Researchers use machine learning to predict how ingested drugs will interact with transport proteins

World Pharma News - Wed, 02/21/2024 - 11:00
Before orally administered drugs can make their way throughout the body, they must first bind to membrane proteins called drug transporters, which carry compounds across the intestinal tract and help them reach their intended targets. But because one drug can bind to several different drug transporters, they may struggle to get past this gut barrier, potentially leading to decreased drug absorption and efficacy.

New model identifies drugs that shouldn’t be taken together

World Pharma News - Tue, 02/20/2024 - 11:00
Any drug that is taken orally must pass through the lining of the digestive tract. Transporter proteins found on cells that line the GI tract help with this process, but for many drugs, it’s unknown which of those transporters they use to exit the digestive tract.

Identifying the transporters used by specific drugs could help to improve patient treatment because if two drugs rely on the same transporter, they can interfere with each other and should not be prescribed together.

Acquisition of Icosavax completed

World Pharma News - Mon, 02/19/2024 - 11:00
AstraZeneca announced today the successful completion of the acquisition of Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. As a result of the acquisition, Icosavax has become a subsidiary of AstraZeneca, with operations in Seattle, US.

UIC research helps create new antibiotic that evades bacterial resistance

World Pharma News - Fri, 02/16/2024 - 11:00
Scientists at the University of Illinois Chicago and Harvard University have developed an antibiotic that could give medicine a new weapon to fight drug-resistant bacteria and the diseases they cause.

The antibiotic, cresomycin, described in Science, effectively suppresses pathogenic bacteria that have become resistant to many commonly prescribed antimicrobial drugs.

First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure

World Pharma News - Thu, 02/15/2024 - 11:00
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002 (also known as NAN-101) for the treatment of congestive heart failure (CHF).

Clinical trial shows rheumatoid arthritis drug could prevent disease

World Pharma News - Wed, 02/14/2024 - 11:00
A drug used to treat rheumatoid arthritis could also prevent the disease in individuals deemed to be at risk.

Results from a Phase 2b clinical trial, published in The Lancet by researchers led by King's College London, provides hope for arthritis sufferers after it was shown that the biologic drug abatacept reduces progression to this agonising chronic inflammatory disease.

Cleveland Clinic research reveals unique tumor-related bacteria tied to young-onset colorectal cancer

World Pharma News - Tue, 02/13/2024 - 11:00
New research from global health system Cleveland Clinic has mapped changes in tumor-related bacteria to uncover potential new strategies to combat the rise of young-onset colorectal cancer (CRC) in people under the age of 50.

The research reveals differences in tumor-related bacteria associated with young-onset colorectal cancer.

Vaccine shows promise against CMV, a virus that causes birth defects

World Pharma News - Mon, 02/12/2024 - 11:00
An experimental mRNA vaccine against human cytomegalovirus (CMV), a common virus that can infect babies during pregnancy, elicited some of the most promising immune responses to date of any CMV vaccine candidate, according to a study by Weill Cornell Medicine investigators.

Using cancer's strength to fight against it

World Pharma News - Fri, 02/09/2024 - 11:00
Scientists at the UC San Francisco (UCSF) and Northwestern Medicine may have found a way around the limitations of engineered T cells by borrowing a few tricks from cancer itself.

By studying mutations in malignant T cells that cause lymphoma, they zeroed in on one that imparted exceptional potency to engineered T cells. Inserting a gene encoding this unique mutation into normal human T cells made them more than 100 times more potent at killing cancer cells without any signs of becoming toxic.

Chapman scientists code ChatGPT to design new medicine

World Pharma News - Thu, 02/08/2024 - 11:00
Generative artificial intelligence platforms, from ChatGPT to Midjourney, grabbed headlines in 2023. But GenAI can do more than create collaged images and help write emails - it can also design new drugs to treat disease.

Today, scientists use advanced technology to design new synthetic drug compounds with the right properties and characteristics, also known as "de novo drug design." However, current methods can be labor-, time-, and cost-intensive.

Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor

World Pharma News - Wed, 02/07/2024 - 11:00
Vividion Therapeutics, Inc. (Vividion), announced that it has initiated dosing of patients in a Phase I clinical trial evaluating VVD-130850, an investigational oral STAT3 inhibitor for the treatment of advanced solid and hematologic tumors. Vividion is a biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG,

MSU researchers find early, promising glioblastoma treatment

World Pharma News - Tue, 02/06/2024 - 11:00
A team of Michigan State University scientists has unveiled a potential game-changer in the fight against glioblastoma, the most common and currently incurable form of brain cancer.

A team of Michigan State University scientists has unveiled a potential game-changer in the fight against glioblastoma, the most common and currently incurable form of brain cancer.

The American Cancer Society and Pfizer announce a $15 million, three-year initiative to bridge the gap in cancer care disparities

World Pharma News - Mon, 02/05/2024 - 11:00
The American Cancer Society (ACS) and Pfizer Inc. (NYE: PFE) today announced the launch of "Change the Odds: Uniting to Improve Cancer Outcomes™," a three-year initiative to bridge the gap in cancer care disparities. Through $15 million in funding from Pfizer, the initiative aims to improve health outcomes in medically underrepresented communities across the United States by enhancing awareness of and access to cancer screenings, clinical trial opportunities, and patient support and comprehensive navigation.

Cheating death: How cancer cells escape

World Pharma News - Fri, 02/02/2024 - 11:00
Cell death is fundamental to life and, thus, healthy aging. In the realm of cellular biology, ferroptosis (a form of programmed cell death) has emerged not only as a focal point of research for its potential in eliminating cancer cells, but also its role in a plethora of other diseases, including neurodegenerative diseases such as Alzheimer's disease, eye diseases such as Retinitis pigmentosa and age-related macular degeneration, as well as ischemia, cardiovascular disease, liver disease, acute kidney injury and inflammation.